X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12) 12
humans (9) 9
aged (8) 8
hematology (8) 8
male (7) 7
female (6) 6
middle aged (6) 6
therapy (6) 6
abridged index medicus (5) 5
dexamethasone (5) 5
multiple myeloma - drug therapy (5) 5
adult (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
bortezomib (4) 4
care and treatment (4) 4
hemic and lymphatic diseases (4) 4
lenalidomide (4) 4
multiple myeloma (4) 4
multiple myeloma - mortality (4) 4
oncology (4) 4
survival (4) 4
aged, 80 and over (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
article (3) 3
dexamethasone - administration & dosage (3) 3
disease-free survival (3) 3
expression (3) 3
induction (3) 3
multiple myeloma - diagnosis (3) 3
multiple myeloma - pathology (3) 3
multiple myeloma - therapy (3) 3
prognosis (3) 3
prognostic value (3) 3
thalidomide - administration & dosage (3) 3
thalidomide - analogs & derivatives (3) 3
transplantation (3) 3
treatment outcome (3) 3
antineoplastic agents - therapeutic use (2) 2
carfilzomib (2) 2
criteria (2) 2
cyclophosphamide (2) 2
dosage and administration (2) 2
drug therapy (2) 2
exanthema (2) 2
flow cytometry (2) 2
flow-cytometry (2) 2
gene expression profiling (2) 2
genetic aspects (2) 2
immunophenotyping (2) 2
initial treatment (2) 2
maintenance (2) 2
melphalan (2) 2
minimal residual disease (2) 2
multiparameter flow-cytometry (2) 2
multiple myeloma - genetics (2) 2
multiple-myeloma (2) 2
neoplasm, residual (2) 2
phenotype (2) 2
plasma cells - metabolism (2) 2
plasma cells - pathology (2) 2
prednisone (2) 2
prednisone - therapeutic use (2) 2
prognostic-factor (2) 2
proportional hazards models (2) 2
proteasome inhibitors (2) 2
spain (2) 2
stem-cell transplantation (2) 2
survival analysis (2) 2
survival rate (2) 2
thalidomide (2) 2
thrombocytopenia (2) 2
young adult (2) 2
3-year follow-up (1) 1
abl protein (1) 1
adhesion (1) 1
administration, oral (1) 1
adolescent (1) 1
age factors (1) 1
analysis (1) 1
anemia (1) 1
antigens, cd - metabolism (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antitumor-activity (1) 1
articles (1) 1
b-cells (1) 1
bcr protein (1) 1
bcr-abl (1) 1
bcr-abl positive (1) 1
biomarkers (1) 1
biomarkers, pharmacological - blood (1) 1
biomarkers, tumor - blood (1) 1
bleomycin - adverse effects (1) 1
bleomycin - therapeutic use (1) 1
body regions (1) 1
bone marrow - metabolism (1) 1
bone marrow - pathology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2017, Volume 35, Issue 25, pp. 2900 - 2910
Journal Article
Blood, ISSN 0006-4971, 01/2012, Volume 119, Issue 3, pp. 687 - 691
Journal Article
Blood, ISSN 0006-4971, 06/2016, Volume 127, Issue 25, pp. 3165 - 3174
Journal Article
Leukemia, ISSN 0887-6924, 02/2017, Volume 31, Issue 2, pp. 382 - 392
Journal Article
Journal Article
American Journal of Pathology, The, ISSN 0002-9440, 2012, Volume 181, Issue 5, pp. 1870 - 1878
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 402 - 402
Abstract MRD monitoring is emerging as a powerful prognostic biomarker in MM. In addition to its utility to redefine the depth of response achieved after... 
Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 08/2018, Volume 103, Issue 9, pp. 1518 - 1526
This phase I/II dose-escalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent ixazomib maintenance, in... 
TRIAL | PLUS LENALIDOMIDE-DEXAMETHASONE | WORKING GROUP | PROTEASOME INHIBITOR IXAZOMIB | TWICE-WEEKLY IXAZOMIB | UP DATA | INITIAL TREATMENT | OPEN-LABEL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Index Medicus
Journal Article
European Journal of Haematology, ISSN 0902-4441, 06/2019, Volume 102, Issue 6, pp. 494 - 503
To evaluate the safety and efficacy of maintenance therapy with the oral proteasome inhibitor ixazomib in patients with newly diagnosed multiple myeloma (NDMM)... 
multiple myeloma | clinical trials | Medical research | Cyclophosphamide | Dexamethasone | Multiple myeloma | Clinical trials | Medicine, Experimental | Development and progression | Prednisone | Toxicity | Melphalan | Transplantation | Proteasome inhibitors
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 3390 - 3390
Abstract The genetic heterogeneity of multiple myeloma (MM) makes it unlikely that established or novel chemotherapy could be equally effective in all genetic... 
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 4068 - 4068
Abstract Abstract 4068 Background: The efficacy and tolerability of LEN in pts with RRMM has been demonstrated in 2 large, randomized, phase 3 studies... 
Journal Article